Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2013

Conditions
Cerebral Palsy (CP)
Interventions
DRUG

dalfampridine-ER 10mg

OTHER

Placebo

Trial Locations (11)

21205

Kennedy Krieger Institute at Johns Hopkins University, Baltimore

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic, Cleveland

48334

Detroit Clinical Research Center, Farmington Hills

55101

Gillette Children's Specialty Healthcare, Saint Paul

60611

Rehabilitation Institute of Chicago, Chicago

65212

University of Missouri at Columbia, Columbia

90095

UCLA/Orthopaedic Hospital Center for Cerebral Palsy, Los Angeles

90242

Rancho Los Amigos National Rehabilitation Center, Downey

92123

Rady Children's Hospital San Diego, San Diego

98122

Swedish Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY